Pilot study of Pitolisant, a histamine-3 inverse agonist, as adjunct therapy for refractory restless legs syndrome

Keyphrases

• Inverse Agonist 100%
• Restless Legs Syndrome 100%
• Adjunct Therapy 100%
• Pitolisant 100%
• Histamine H3 100%
• Opioids 18%
• Gabapentinoids 18%
• Stimulants 9%
• Adverse Events 9%
• Lost to Follow-up 9%
• Maximum Tolerated Dose 9%
• Family History 9%
• Open-label Trial 9%
• Histamine 9%
• Rating Scales 9%
• Insomnia 9%
• Narcolepsy 9%
• Epworth Sleepiness Scale 9%
• Sleepiness 9%
• Blood-brain 9%
• International Restless Legs Syndrome Rating Scale 9%
• Dual Therapy 9%
• Daytime Consequences 9%
• Sedating Antihistamines 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Histamine 100%
• Inverse Agonist 100%
• Restless Legs Syndrome 100%
• Pitolisant 100%
• Dopamine Receptor Stimulating Agent 16%
• Gabapentinoid 16%
• Adverse Event 8%
• Iron 8%
• Antihistaminic Agent 8%
• Somnolence 8%
• Open-Label Trial 8%
• Attention Deficit Disorder 8%
• Narcolepsy 8%